Suppr超能文献

血小板活化因子可增加特定组织的血管通透性:BN - 52021和L - 655,240的作用

PAF increases vascular permeability in selected tissues: effect of BN-52021 and L-655,240.

作者信息

Sirois M G, Jancar S, Braquet P, Plante G E, Sirois P

机构信息

Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, P.Q., Canada.

出版信息

Prostaglandins. 1988 Nov;36(5):631-44. doi: 10.1016/0090-6980(88)90009-3.

Abstract

The effect of the potent inflammatory mediator, platelet activating factor (PAF) was studied on the vascular permeability of selected rat tissues using the extravasation of Evans blue dye (EB) as a marker. EB (20 mg/kg) was injected in the caudal vein together with increasing doses of PAF (0.1, 1.0 and 5.0 micrograms/kg). The animals were killed and the dye was extracted in selected organs using formamide (4 ml/g wet weight tissues) and the content was expressed as EB micrograms/g dry weight. Extravasation of EB varied markedly from one tissue to another and increased as a function of time (from 0 to 60 min). PAF (5.0 micrograms/kg) increased the pancreas and duodenum vascular permeability by 15 and 5 fold respectively. At the doses of 0.1 and 1.0 microgram/kg, PAF induced a slight increase (P less than 0.01) of the vascular permeability of the heart 5 min after the injection. The PAF antagonist BN-52021 (2 and 10 mg/kg) produced a dose-dependent inhibition of the PAF effects on the pancreas, heart and duodenum. Maximum inhibition (approximately 100%) was achieved at the dose of 10 mg/kg. This antagonist given in the absence or the presence of PAF reduced the lung plasma extravasation below control levels. A thromboxane antagonist, L-655,240 (1.0 and 5.0 mg/kg) also inhibited PAF-induced increases in vascular permeability in heart, duodenum and pancreas. It also reduced below control levels the EB extravasation in kidneys, spleen and lungs. Maximum inhibition (50% for the duodenum, and 40% for the pancreas) was achieved at the dose of 5.0 mg/kg.

摘要

以伊文思蓝染料(EB)外渗作为标志物,研究了强效炎症介质血小板活化因子(PAF)对特定大鼠组织血管通透性的影响。将EB(20mg/kg)与递增剂量的PAF(0.1、1.0和5.0微克/千克)一起经尾静脉注射。处死动物后,使用甲酰胺(4ml/g湿重组织)从选定器官中提取染料,其含量以EB微克/克干重表示。EB的外渗在不同组织间差异显著,并随时间(从0到60分钟)而增加。PAF(5.0微克/千克)分别使胰腺和十二指肠的血管通透性增加了15倍和5倍。在0.1和1.0微克/千克的剂量下,PAF在注射后5分钟使心脏的血管通透性略有增加(P<0.01)。PAF拮抗剂BN - 52021(2和10mg/kg)对PAF对胰腺、心脏和十二指肠的作用产生剂量依赖性抑制。在10mg/kg的剂量下达到最大抑制(约100%)。在不存在或存在PAF的情况下给予该拮抗剂,均可使肺血浆外渗降至对照水平以下。血栓素拮抗剂L - 655,240(1.0和5.0mg/kg)也抑制PAF诱导的心脏、十二指肠和胰腺血管通透性增加。它还使肾脏、脾脏和肺中的EB外渗降至对照水平以下。在5.0mg/kg的剂量下达到最大抑制(十二指肠为50%,胰腺为40%)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验